Canakinumab - Cryopyrin-associated periodic syndromes (CAPS) Medicine

Canakinumab used to treat a rare hereditary disease called Cryopyrin-associated periodic syndromes (CAPS), including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS). CAPS is a disease that occurs when the body produces too much of a specific natural protein produced by the body called interleukin-1 beta.

These drugs work by inhibiting the protein interleukin-1 beta, which can worsen the symptoms of CAPS. However Canakinumab not necessarily cure CAPS, these drugs can only reduce symptoms such as rash, muscle pain / joints, fever, red eyes and fatigue.

The drug in powder form for the injected solution can only be given by a doctor or nurse under the direct supervision of a doctor.


- Reduces the symptoms of Cryopyrin-associated periodic syndromes (CAPS).
- To prevent inflammation caused by too much interleukin-1 beta produced



Post a Comment